Steven N Quayle
Overview
Explore the profile of Steven N Quayle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seidel R, Merazga Z, Thapa D, Soriano J, Spaulding E, Vakkasoglu A, et al.
Sci Rep
. 2021 Sep;
11(1):19220.
PMID: 34584159
Targeted pharmacologic activation of antigen-specific (AgS) T cells may bypass limitations inherent in current T cell-based cancer therapies. We describe two immunotherapeutics platforms for selective delivery of costimulatory ligands and...
2.
Quayle S, Girgis N, Thapa D, Merazga Z, Kemp M, Histed A, et al.
Clin Cancer Res
. 2020 Jan;
26(8):1953-1964.
PMID: 31964784
Purpose: To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E7-specific CD8 T cells as an off-the shelf therapy for the treatment...
3.
Dasmahapatra G, Patel H, Friedberg J, Quayle S, Jones S, Grant S
Mol Cancer Ther
. 2019 Jun;
18(6):1181.
PMID: 31160511
No abstract available.
4.
Maharaj K, Powers J, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al.
Blood Adv
. 2018 Nov;
2(21):3012-3024.
PMID: 30425065
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist...
5.
Liu Y, Li Y, Liu S, Adeegbe D, Christensen C, Quinn M, et al.
Cancer Res
. 2018 May;
78(13):3709-3717.
PMID: 29760044
Small-cell lung cancer (SCLC) has the highest malignancy among all lung cancers, exhibiting aggressive growth and early metastasis to distant sites. For 30 years, treatment options for SCLC have been...
6.
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, et al.
Breast Cancer Res
. 2017 Apr;
19(1):49.
PMID: 28424080
No abstract available.
7.
Adeegbe D, Liu Y, Lizotte P, Kamihara Y, Aref A, Almonte C, et al.
Cancer Discov
. 2017 Apr;
7(8):852-867.
PMID: 28408401
Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to...
8.
North B, Almeciga-Pinto I, Tamang D, Yang M, Jones S, Quayle S
PLoS One
. 2017 Mar;
12(3):e0173507.
PMID: 28264055
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including...
9.
Min C, Moore N, Shearstone J, Quayle S, Huang P, van Duzer J, et al.
PLoS One
. 2017 Jan;
12(1):e0169128.
PMID: 28060870
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients...
10.
Huang P, Almeciga-Pinto I, Jarpe M, van Duzer J, Mazitschek R, Yang M, et al.
Oncotarget
. 2016 Dec;
8(2):2694-2707.
PMID: 27926524
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat),...